Zacks Investment Research upgraded shares of Cellectis (NASDAQ:CLLS) from a hold rating to a buy rating in a research note published on Friday. The brokerage currently has $25.00 price target on the biotechnology company’s stock.

According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “

Several other research analysts have also recently issued reports on the company. BidaskClub cut Cellectis from a hold rating to a sell rating in a research note on Monday, November 12th. ValuEngine raised Cellectis from a hold rating to a buy rating in a research note on Thursday, November 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $48.00.

Shares of NASDAQ:CLLS opened at $22.00 on Friday. Cellectis has a 52-week low of $21.29 and a 52-week high of $38.85. The company has a market capitalization of $915.32 million, a P/E ratio of -7.91 and a beta of 1.76.

A number of hedge funds and other institutional investors have recently made changes to their positions in CLLS. Wells Fargo & Company MN boosted its position in Cellectis by 101.8% during the 1st quarter. Wells Fargo & Company MN now owns 27,483 shares of the biotechnology company’s stock valued at $866,000 after acquiring an additional 13,866 shares in the last quarter. UBS Group AG boosted its position in Cellectis by 143.1% during the 1st quarter. UBS Group AG now owns 15,383 shares of the biotechnology company’s stock valued at $485,000 after acquiring an additional 9,054 shares in the last quarter. P.A.W. Capital Corp boosted its position in Cellectis by 196.3% during the 2nd quarter. P.A.W. Capital Corp now owns 40,000 shares of the biotechnology company’s stock valued at $1,132,000 after acquiring an additional 26,500 shares in the last quarter. Eqis Capital Management Inc. boosted its position in Cellectis by 21.2% during the 2nd quarter. Eqis Capital Management Inc. now owns 35,547 shares of the biotechnology company’s stock valued at $1,006,000 after acquiring an additional 6,213 shares in the last quarter. Finally, Commonwealth Equity Services LLC bought a new stake in Cellectis during the 2nd quarter valued at $237,000. 27.36% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Read More: Depreciation

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.